Cited by 115Treatment of Major DepressionMental Health Treatment and AccessAnxiety, Depression, Psychometrics, Treatment, Cognitive Processes

The DOI matches its Crossref record; 14 of the 15 references it cites were found in a registry or an index.

Sequenced Treatment Alternatives to Relieve Depression (STAR*D): Part 2: Study Outcomes

Howland, Robert H.·2008·Journal of Psychosocial Nursing and Mental Health Services

DOI 10.3928/02793695-20081001-05

Open this paper in CoChat — free account

Abstract

This article reviews the main outcome findings from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study. The study compared the efficacy and tolerability of a range of antidepressant therapies through four sequential levels of treatment with the goal of achieving remission. Remission rates based on the primary outcome measure (Hamilton Rating Scale for Depression) were 28% (Level 1 citalopram), 17% to 30% (Level 2 treatments), 12% to 25% (Level 3 treatments), and 7% to 14% (Level 4 treatments). For patients not responding adequately to an initial trial of citalopram, subsequent treatment strategies may be effective. When more treatment steps are required, however, lower acute remission rates, greater degrees of treatment intolerance, and higher relapse rates during follow up are seen. There were few differences among treatments within each level related to efficacy or tolerability, although patients had clear preferences for or against certain treatments.

Integrity signals

Registry

Crossref · 10.3928/02793695-20081001-05

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Self-citation
Sequenced treatment alternatives to relieve depression (STAR*D): Rationale and design
Rush, A. J., Fava, M., Wisniewski, S. R., Lavori, P. W., Trivedi, M. H., Sackeim, H. A., Thase, M. E., Nierenberg, A. A., Quitkin, F. M., Kashner, T. M., et al. (2004) · Controlled Clinical Trials · doi:10.1016/s0197-2456(03)00112-0 · Cited by 1,076
Bupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Stewart, J. W., Nierenberg, A. A., Thase, M. E., Ritz, L., Biggs, M. M., Warden, D., Luther, J. F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052963 · Cited by 1,033
Medication Augmentation after the Failure of SSRIs for Depression
Trivedi, M. H., Fava, M., Wisniewski, S. R., Thase, M. E., Quitkin, F., Warden, D., Ritz, L., Nierenberg, A. A., Lebowitz, B. D., Biggs, M. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052964 · Cited by 1,002
Difference in treatment outcome in outpatients with anxious versus nonanxious depression: A STAR*D report
Fava, M., Rush, A. J., Alpert, J. E., Balasubramani, G. K., Wisniewski, S. R., Carmin, C. N., Biggs, M. M., Zisook, S., Leuchter, A., Howland, R., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.06111868 · Cited by 927
Self-citation
A Comparison of Lithium and T 3 Augmentation Following Two Failed Medication Treatments for Depression: A STAR*D Report
Nierenberg, A. A., D, M. F. M., Trivedi, M. H., Wisniewski, S. R., Thase, M. E., McGrath, P. J., Alpert, J. E., Warden, D., Luther, J. F., Niederehe, G., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.9.1519 · Cited by 585
A Comparison of Mirtazapine and Nortriptyline Following Two Consecutive Failed Medication Treatments for Depressed Outpatients: A STAR*D Report
D, M. F. M., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Alpert, J. E., McGrath, P. J., Thase, M. E., Warden, D., Biggs, M. M., Luther, J. F., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.7.1161 · Cited by 367
Tranylcypromine Versus Venlafaxine Plus Mirtazapine Following Three Failed Antidepressant Medication Trials for Depression: A STAR*D Report
McGrath, P. J., Stewart, J. W., D, M. F. M., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Thase, M. E., Davis, L. L., Biggs, M. M., Shores‐Wilson, K., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.9.1531 · Cited by 350
Cognitive Therapy Versus Medication in Augmentation and Switch Strategies as Second-Step Treatments: A STAR*D Report
Thase, M. E., Friedman, E. S., Biggs, M. M., Wisniewski, S. R., Trivedi, M. H., Luther, J. F., Fava, M., Nierenberg, A. A., McGrath, P. J., Warden, D., et al. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.5.739 · Cited by 332

Show all 15 references

Research works printed but not linked: 2

10.1176/ajp.2006.163.7.1161 · DOI
Gilmer, W.S., Gollan, J.K., Wisniewski, S.R., Howland, R.H., Trivedi, M.H., Miyahara, S., . (in press). Does the duration of index episode affect the treatment outcome of major depressive disorder? A STAR*D report. Journal of Clinical Psychiatry.

Sorted by citations

Closed-loop neuromodulation in an individual with treatment-resistant depression
Scangos, K. W., Khambhati, A. N., Daly, P. M., Makhoul, G. S., Sugrue, L. P., Zamanian, H., Liu, T. X., Rao, V. R., Sellers, K. K., Dawes, H. E., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01480-w · Cited by 535
State-dependent responses to intracranial brain stimulation in a patient with depression
Scangos, K. W., Makhoul, G. S., Sugrue, L. P., Chang, E. F., & Krystal, A. D. (2021) · Nature Medicine · doi:10.1038/s41591-020-01175-8 · Cited by 243
Modulation of serum brain-derived neurotrophic factor by a single dose of ayahuasca: observation from a randomized controlled trial
Almeida, R. N. D., Galvão, A. C. D. M., da Silva, F. S., Silva, E. A. D. S., Palhano-Fontes, F., Maia-de-Oliveira, J. P., de Araújo, L.-S. B., Lobão-Soares, B., & Galvão-Coelho, N. L. (2019) · Frontiers in Psychology · doi:10.3389/fpsyg.2019.01234 · Cited by 177
Rapid inflammation modulation and antidepressant efficacy of a low-dose ketamine infusion in treatment-resistant depression: A randomized, double-blind control study
Chen, M.-H., Li, C.-T., Lin, W.-C., Hong, C.-J., Tu, P.-C., Bai, Y.-M., Cheng, C.-M., & Su, T.-P. (2018) · Psychiatry Research · doi:10.1016/j.psychres.2018.08.078 · Cited by 159
The role of neuroinflammation and neurovascular dysfunction in major depressive disorder
Jeon, S. W., & Kim, Y. (2018) · Journal of Inflammation Research · doi:10.2147/jir.s141033 · Cited by 123
Cognitive function of patients with treatment-resistant depression after a single low dose of ketamine infusion
Chen, M.-H., Li, C.-T., Lin, W.-C., Hong, C.-J., Tu, P.-C., Bai, Y.-M., Cheng, C.-M., & Su, T.-P. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.07.033 · Cited by 86
Asperosaponin VI ameliorates the CMS-induced depressive-like behaviors by inducing a neuroprotective microglial phenotype in hippocampus via PPAR-γ pathway
Jiang, X., Yi, S., Liu, Q., Su, D., Li, L., Xiao, C., & Zhang, J. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02478-y · Cited by 89
Maintenance of antidepressant and antisuicidal effects by D-cycloserine among patients with treatment-resistant depression who responded to low-dose ketamine infusion: a double-blind randomized placebo–control study
Chen, M.-H., Cheng, C.-M., Gueorguieva, R., Lin, W.-C., Li, C.-T., Hong, C.-J., Tu, P.-C., Bai, Y.-M., Tsai, S.-J., Krystal, J. H., et al. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-019-0480-y · Cited by 84
Cohort profile: the Australian genetics of depression study
Byrne, E. M., Kirk, K. M., Medland, S. E., McGrath, J. J., Colodro‐Conde, L., Parker, R., Cross, S., Sullivan, L., Statham, D. J., Levinson, D. F., et al. (2020) · BMJ Open · doi:10.1136/bmjopen-2019-032580 · Cited by 79
Investigational drugs in recent clinical trials for treatment-resistant depression
Garay, R. P., Zarate, C. A., Charpeaud, T., Citrome, L., Correll, C. U., Hameg, A., & Llorca, P. (2017) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2017.1283217 · Cited by 76
Physiologically Relevant Changes in Serotonin Resolved by Fast Microdialysis
Yang, H., Thompson, A. B., McIntosh, B. J., Altieri, S. C., & Andrews, A. M. (2013) · ACS Chemical Neuroscience · doi:10.1021/cn400072f · Cited by 73
NMDA antagonist treatment of depression
Williams, N., & Schatzberg, A. F. (2015) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2015.11.001 · Cited by 68
Frequency, Characteristics and Management of Adolescent Inpatient Aggression
Baeza, I., Correll, C. U., Saito, E., Amanbekova, D., Ramani, M., Kapoor, S., Chekuri, R., Binder, M. D., & Carbon, M. (2013) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2012.0116 · Cited by 63
Combined sleep deprivation and light therapy: clinical treatment outcomes in patients with complex unipolar and bipolar depression
Sikkens, D., Riemersma - Van der Lek, R. F., Meesters, Y., Schoevers, R. A., & Haarman, B. C. M. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.12.117 · Cited by 48
Pleiotropic genes in psychiatry: Calcium channels and the stress-related FKBP5 gene in antidepressant resistance
Fabbri, C., Corponi, F., Albani, D., Raimondi, I., Forloni, G., Schruers, K. R. J., Kasper, S. F., Kautzky, A., Zohar, J., Souery, D., et al. (2017) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.10.005 · Cited by 48
Five-Year Follow-Up of Bilateral Epidural Prefrontal Cortical Stimulation for Treatment-Resistant Depression
Williams, N., Short, E. B., Hopkins, T., Bentzley, B. S., Sahlem, G. L., Pannu, J., Schmidt, M., Borckardt, J. J., Korte, J. E., George, M. S., et al. (2016) · Brain stimulation · doi:10.1016/j.brs.2016.06.054 · Cited by 46
Increased Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Levels in Plasma of Suicide Attempters
Ventorp, F., Gustafsson, A., Träskman‐Bendz, L., Westrin, Å., & Ljunggren, L. (2015) · PLoS ONE · doi:10.1371/journal.pone.0140052 · Cited by 42
Current Nosology of Treatment Resistant Depression: A Controversy Resistant to Revision
Fornaro, M., & Giosuè, P. (2010) · Clinical Practice and Epidemiology in Mental Health · doi:10.2174/1745017901006010020 · Cited by 43
New insights into the neurobiological mechanisms of major depressive disorders
Fakhoury, M. (2015) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2015.01.005 · Cited by 45
PPP3CC gene: a putative modulator of antidepressant response through the B-cell receptor signaling pathway
Fabbri, C., Marsano, A., Albani, D., Chierchia, A., Calati, R., Drago, A., Crisafulli, C., Calabrò, M., Kasper, S. F., Lanzenberger, R. R., et al. (2014) · The Pharmacogenomics Journal · doi:10.1038/tpj.2014.15 · Cited by 41
Projecting the 10-year costs of care and mortality burden of depression until 2032: a Markov modelling study developed from real-world data
Chan, V. K. Y., Leung, M. Y. M., Chan, S. S. M., Yang, D., Knapp, M. R. J., Luo, H., Craig, D., Chen, Y., Bishai, D. M., Wong, G. H. Y., et al. (2024) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2024.101026 · Cited by 45
Metabolomics Biomarkers for Precision Psychiatry
Shih, P.-A. B. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-21735-8_10 · Cited by 41
Catechol O-methyltransferase pharmacogenomics and selective serotonin reuptake inhibitor response
Ji, Y., Biernacka, J. M., Snyder, K., Drews, M., Pelleymounter, L. L., Colby, C., Wang, L., Mrazek, D. A., & Weinshilboum, R. M. (2010) · The Pharmacogenomics Journal · doi:10.1038/tpj.2010.69 · Cited by 40
Neuronal cell adhesion genes and antidepressant response in three independent samples
Fabbri, C., Crisafulli, C., Gurwitz, D., Stingl, J., Calati, R., Albani, D., Forloni, G., Calabrò, M., Martines, R., Kasper, S. F., et al. (2015) · The Pharmacogenomics Journal · doi:10.1038/tpj.2015.15 · Cited by 37
Sex dependence of opioid-mediated responses to subanesthetic ketamine in rats
Ianni, T. D., Ewbank, S. N., Levinstein, M. R., Azadian, M. M., Budinich, R. C., Michaelides, M., & Airan, R. D. (2024) · Nature Communications · doi:10.1038/s41467-024-45157-7 · Cited by 33
Cost–Utility Analysis of Electroconvulsive Therapy and Repetitive Transcranial Magnetic Stimulation for Treatment-Resistant Depression in Ontario
Fitzgibbon, K. P., Plett, D., Chan, B., Hancock, R., Coyte, P. C., & Blumberger, D. M. (2019) · The Canadian Journal of Psychiatry · doi:10.1177/0706743719890167 · Cited by 35
Immunoregulation and antidepressant effect of ketamine
Zhang, N., Yao, L., Wang, P., & Liu, Z. (2021) · Translational Neuroscience · doi:10.1515/tnsci-2020-0167 · Cited by 35
Depressive-like behaviours and decreased dendritic branching in the medial prefrontal cortex of mice with tumors: A novel validated model of cancer-induced depression
Nashed, M. G., Seidlitz, E. P., Frey, B. N., & Singh, G. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.07.040 · Cited by 37
Efficacy and acceptability of second-generation antipsychotics with antidepressants in unipolar depression augmentation: a systematic review and network meta-analysis
Yan, Y., Xiao, Y., Wang, M., Chen, B., Yin, L., & Ma, X. (2022) · Psychological Medicine · doi:10.1017/s0033291722001246 · Cited by 32
Intermittent Fasting as a Potential Therapeutic Instrument for Major Depression Disorder: A Systematic Review of Clinical and Preclinical Studies
Nery, L. D. D. M., Seixas, D., Harada, L., Damiano, R. F., & Zanetti, M. V. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242115551 · Cited by 33
Lateral Habenula Gone Awry in Depression: Bridging Cellular Adaptations With Therapeutics
Nuno‐Perez, A., Tchenio, A., Mameli, M., & Lecca, S. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00485 · Cited by 31
Changes in Cortisol but Not in Brain-Derived Neurotrophic Factor Modulate the Association Between Sleep Disturbances and Major Depression
Santiago, G. T. P., Galvão, A. C. D. M., de Almeida, R. N., Mota-Rolim, S. A., Palhano-Fontes, F., Maia‐de‐Oliveira, J. P., de Araújo, D. B., Soares, B. L., & Coelho, N. L. G. (2020) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2020.00044 · Cited by 31
Edible Mushrooms as a Potential Component of Dietary Interventions for Major Depressive Disorder
Fijałkowska, A., Jędrejko, K., Sułkowska‐Ziaja, K., Ziaja, M., Kała, K., & Muszyńska, B. (2022) · Foods · doi:10.3390/foods11101489 · Cited by 31
A randomized, double-blind study of the efficacy and tolerability of extended-release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder
Wang, G., McIntyre, A., Earley, Raines, S. R., & Eriksson, H. (2014) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s50248 · Cited by 29
Treatment-resistant depression and risk of autoimmune diseases: evidence from a population-based cohort and nested case-control study
Chan, V. K. Y., Luo, H., Chan, S. S. M., Lau, C. S., Yeung, W. W. Y., Peng, K., Tong, X., Lam, M. P. S., Wong, I. C. K., & Li, X. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02383-9 · Cited by 27
Research objectives and general considerations for pragmatic clinical trials of pain treatments: IMMPACT statement
Hohenschurz‐Schmidt, D., Cherkin, D. C., Rice, A. S. C., Dworkin, R. H., Turk, D. C., McDermott, M. P., Bair, M. J., DeBar, L., Edwards, R. R., Farrar, J. T., et al. (2023) · Pain · doi:10.1097/j.pain.0000000000002888 · Cited by 28
Characterizing, Assessing, and Treating Cognitive Dysfunction in Major Depressive Disorder
McIntyre, R. S., Lee, Y. L., Carmona, N. E., Subramaniapillai, M., Cha, D. S., Lee, J., Lee, J.-H., Alageel, A. A. S., Rodrigues, N. B., Park, C., et al. (2018) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000171 · Cited by 30
Efficacy and acceptability of psilocybin for primary or secondary depression: A systematic review and meta-analysis of randomized controlled trials
Fang, S., Yang, X., & Zhang, W. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1359088 · Cited by 34
Pathophysiology of Major Depression by Clinical Stages
de Menezes Galvão, A. C., Almeida, R. N., de Sousa, G. M., Leocadio-Miguel, M. A., Palhano-Fontes, F., de Araujo, D. B., Lobão-Soares, B., Maia-de-Oliveira, J. P., Nunes, E. A., Hallak, J. E. C., et al. (2021) · Frontiers in Psychology · doi:10.3389/fpsyg.2021.641779 · Cited by 31
Using classification and regression tree modelling to investigate treatment response to a single low-dose ketamine infusion: Post hoc pooled analyses of randomized placebo-controlled and open-label trials
Chen, M., Wu, H.-J., Li, C., Lin, W.-C., Bai, Y., Tsai, S., Hong, C., Tu, P., Cheng, C., & Su, T. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.11.045 · Cited by 24
Neuroplasticity and second messenger pathways in antidepressant efficacy: pharmacogenetic results from a prospective trial investigating treatment resistance
Fabbri, C., Crisafulli, C., Calati, R., Albani, D., Forloni, G., Calabrò, M., Martines, R., Kasper, S. F., Zohar, J., Juven‐Wetzler, A., et al. (2017) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-017-0766-1 · Cited by 25
Application of the Transtheoretical Model and Social Marketing to Antidepression Campaign Websites
Levit, T., Cismaru, M., & Zederayko, A. (2016) · Social Marketing Quarterly · doi:10.1177/1524500415620138 · Cited by 18
Evaluation of QTc prolongation and dosage effect with citalopram
McClelland, J., & Mathys, M. (2016) · Mental Health Clinician · doi:10.9740/mhc.2016.07.165 · Cited by 18
Impact of fasting on stress systems and depressive symptoms in patients with major depressive disorder: a cross-sectional study
Stapel, B., Fraccarollo, D., Westhoff‐Bleck, M., Bauersachs, J., Lichtinghagen, R., Jahn, K., Burkert, A., Buchholz, V., Bleich, S., Frieling, H., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-11639-1 · Cited by 25
Key considerations for the use of ketamine and esketamine for the treatment of depression: focusing on administration, safety, and tolerability
Kritzer, M. D., Pae, C., & Masand, P. S. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2069749 · Cited by 20
DISC1-TSNAX and DAOA genes in major depression and citalopram efficacy
Arias, B., Fabbri, C., Serretti, A., Drago, A., Mitjans, M., Gastó, C., Catalán, R., & Fañanás, L. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.06.048 · Cited by 20
Collaborative and integrated care for adolescent depression
Kodish, I., Richardson, L., & Schlesinger, A. (2019) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2019.02.003 · Cited by 19
Methods for pragmatic randomized clinical trials of pain therapies: IMMPACT statement
Hohenschurz‐Schmidt, D., Cherkin, D. C., Rice, A. S. C., Dworkin, R. H., Turk, D. C., McDermott, M. P., Bair, M. J., DeBar, L., Edwards, R. R., Evans, S. R., et al. (2024) · Pain · doi:10.1097/j.pain.0000000000003249 · Cited by 19
Association of cognitive impairment and reduced cortical thickness in prefrontal cortex and anterior cingulate cortex with treatment-resistant depression
Chen, M., Chang, W., Tu, P., Lin, W., Li, C., Huang, W.-S., Bai, Y., Tsai, S., & Su, T. (2022) · Brain Imaging and Behavior · doi:10.1007/s11682-021-00613-6 · Cited by 20
Initial Severity Effects on Residual Symptoms in Response and Remission
Madhoo, M., & Levine, S. Z. (2015) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000354 · Cited by 18
Definition and Identification of Patients with Treatment-Resistant Depression in Real-World Clinical Practice Settings Across Asia
Han, C., Wang, G., Chan, S. S. M., Kato, T., Ng, C. H., Tan, W., Zhang, L., Feng, Y., & Liu, C.-Y. (2020) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s264799 · Cited by 18
ASHA: Using Participatory Methods to Develop an Asset-building Mental Health Intervention for Bangladeshi Immigrant Women
Karasz, A., Raghavan, S. S., Patel, V. V., Zaman, M., Akhter, L., & Kabita, M. (2015) · Progress in community health partnerships · doi:10.1353/cpr.2015.0080 · Cited by 18
Baseline Working Memory Predicted Response to Low-Dose Ketamine Infusion in Patients with Treatment-Resistant Depression
Chen, M., Lin, W.-C., Li, C., Tsai, S., Wu, H.-J., Bai, Y., Hong, C., Tu, P., & Su, T. (2021) · Pharmacopsychiatry · doi:10.1055/a-1589-6301 · Cited by 16
Pronounced Regional Variation in Esketamine and Ketamine Prescribing to US Medicaid Patients
Aguilar, A. G., Beauregard, B. A., Conroy, C. P., Khatiwoda, Y. T., Horsford, S. M. E., Nichols, S. D., & Piper, B. J. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2178558 · Cited by 15
Vilazodone
Howland, R. H. (2011) · Journal of Psychosocial Nursing and Mental Health Services · doi:10.3928/02793695-20110203-98 · Cited by 15
Self-citation
Association of Neurofilament Light Chain With the Antidepressant Effects of Low-Dose Ketamine Infusion Among Patients With Treatment-Resistant Depression
Lin, W., Su, T., Li, C., Wu, H.-J., Bai, Y., Liu, Y., Tu, P., & Chen, M. (2023) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyad045 · Cited by 13
Does urinary metabolite signature act as a biomarker of post-stroke depression?
Cai, W., Wang, X., Wei, X.-F., Zhang, J.-R., Hu, C., Ma, W., & Shen, W.-D. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.928076 · Cited by 13
Evidence for the use of vilazodone in the treatment of major depressive disorder
Reinhold, J. A., Mandos, L. A., Lohoff, F. W., & Rickels, K. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.721776 · Cited by 13
Navigating the challenges of substance use and psychopathology in depression, bipolar disorder, and schizophrenia
Chiappini, S., Mosca, A., Semeraro, F., Amerio, A., Berardelli, I., Cremaschi, L., Bernardo, I. D., Pettorruso, M., Serafini, G., Dell’Osso, B. M., et al. (2025) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2025.152616 · Cited by 14
Integrating Patients’ Expectations into the Management of Their Depression: Report of a Symposium at the European College of Neuropsychopharmacology Congress
Demyttenaere, K., Frank, E., Castle, D. J., & Cindik-Herbrüggen, E. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01038-w · Cited by 9
Cortical inhibition function is associated with baseline suicidal symptoms and post-ketamine suicidal symptom reduction among patients with treatment-resistant depression and strong suicidal ideation
Chen, M., Su, T., Chen, L., Li, C., Wu, H.-J., Lin, W., Tsai, S., Bai, Y., Mao, W., Tu, P., et al. (2023) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2023.03.010 · Cited by 10
Brain structural changes underlying clinical symptom improvement following fast-acting treatments in treatment resistant depression
Long, Z., Li, J., & Marino, M. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.09.150 · Cited by 8
Unilateral and bilateral theta burst stimulation for treatment-resistant depression: Follow up on a naturalistic observation study
Elnazali, M., Veerakumar, A., Blair, M., Pearce, E. L., Kim, N., Sebastian, S., Santo, J. B., Rybak, Y. E., & Burhan, A. M. (2024) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2024.10.031 · Cited by 11
Add-on pramipexole for anhedonic depression: study protocol for a randomised controlled trial and open-label follow-up in Lund, Sweden
Lindahl, J., Asp, M., Ståhl, D., Tjernberg, J., Eklund, M., Björkstrand, J., van Westen, D., Jensen, J., Månsson, K. N. T., Tornberg, Å. B., et al. (2023) · BMJ Open · doi:10.1136/bmjopen-2023-076900 · Cited by 8
Impact of a Student Pharmacist Driven Medication Reconciliation and Antidepressant Treatment History Project at a Depression Clinic: A Pilot Study
Tang, S. S., Jaward, L., Ward, K. M., Parikh, S. V., & Bostwick, J. R. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4360 · Cited by 8
Disease progression to bipolar disorder among adolescents and young adults with antidepressant-resistant and antidepressant-responsive depression: Does antidepressant class matter?
Hsu, J.-W., Chen, L.-C., Tsai, S., Huang, K., Bai, Y., Su, T., Chen, M., & Chen, M. (2023) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2023.04.018 · Cited by 8
Challenging Normative Orthodoxies in Depression: Huxley's Utopia or Dante's Inferno?
Cutcliffe, J. R., & Lakeman, R. (2009) · Archives of Psychiatric Nursing · doi:10.1016/j.apnu.2009.06.004 · Cited by 7
Rise of escitalopram and the fall of citalopramPreprint
Cavanah, L. R., Ray, P. K., Goldhirsh, J. L., Huey, L. Y., & Piper, B. J. (2023) · medRxiv · doi:10.1101/2023.05.07.23289632 · Cited by 7
Predicted plasma proteomics from genetic scores and treatment outcomes in major depression: a meta-analysis
Oliva, V., Possidente, C., Fanelli, G., Domschke, K., Minelli, A., Gennarelli, M., Martini, P. G. V., Bortolomasi, M., Squassina, A., Pisanu, C., et al. (2025) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2025.05.004 · Cited by 7
Is psilocybin an effective antidepressant and what is its Mechanism of action?
Mann, J. J. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100906 · Cited by 7
Treatment-Resistant Depression Among US Military Veterans
Lande, R. G. (2019) · Springer eBooks · doi:10.1007/978-3-030-05384-0_7 · Cited by 6
Polygenic scores of subcortical brain volumes as possible modulators of treatment response in depression
Oliva, V., Martone, A., Fanelli, G., Domschke, K., Minelli, A., Gennarelli, M., Martini, P. G. V., Bortolomasi, M., Maron, E., Squassina, A., et al. (2024) · Neuroscience Applied · doi:10.1016/j.nsa.2024.103937 · Cited by 5
Hyponatraemia and confusion in a 70-year-old female when bupropion was added to dothiepin and escitalopram
Wiggins, A., Balasubramanian, T., & Ferraro, A. (2015) · Australasian Psychiatry · doi:10.1177/1039856215597534 · Cited by 4
Barrieren bei der Implementierung pharmakogenetischer Testungen in der Psychiatrie in Deutschland – Ergebnisse aus der FACT-PGx Studie
Hahn, M., Frantz, A. M., Eckert, A. P., & Reif, A. (2023) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/a-2060-0694 · Cited by 4
Metabolites: novel therapeutics or “me-too” drugs? Using desvenlafaxine as an example
Schwartz, T. L. (2012) · CNS Spectrums · doi:10.1017/s1092852912000600 · Cited by 4
SEMIPARAMETRIC REGRESSION ANALYSIS OF REPEATED CURRENT STATUS DATA [
Liang, B., Tong, X., Zeng, D., & Wang, Y. (2017) · Statistica Sinica · doi:10.5705/ss.202014.0153 · Cited by 3
Patterns in (es)citalopram prescriptions to Medicaid and Medicare patients in the United States: the potential effects of evergreening
Cavanah, L. R., Ray, P. K., Goldhirsh, J. L., Huey, L. Y., & Piper, B. J. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1450111 · Cited by 3
Changer d’antidépresseur : quand, comment, pourquoi ?
Gourion, D., Galinowski, A., Baraille, L., & Picard, H. (2011) · L Encéphale · doi:10.1016/j.encep.2010.06.008 · Cited by 3
Clinical applications of electroconvulsive therapy and transcranial magnetic stimulation for the treatment of major depressive disorder: a critical review
Baker, P. L., Treviño, K., McClintock, S. M., Wani, A., & Husain, M. M. (2012) · Neuropsychiatry · doi:10.2217/npy.12.52 · Cited by 3
Antidepressant treatment trajectories and suicide attempt among Australians aged 45 years and older: A population study using individual prescription data
Carter, G. L., Sperandei, S., Chitty, K. M., & Page, A. (2021) · Suicide and Life-Threatening Behavior · doi:10.1111/sltb.12812 · Cited by 3
Monoamine neurotransmitter-related gene-based genome-wide association study of low-dose ketamine in patients with treatment-resistant depression
Kao, C., Tsai, S., Su, T., Li, C., Lin, W.-C., Hong, C., Bai, Y., Tu, P., & Chen, M. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251326939 · Cited by 2
Context as Contraindication: Ethical Challenges of Psychedelics and Other Neuroplasticity-Enhancing Drugs
Langlitz, N., Greenway, K., Pronovost-Morgan, C., & Gainsley, R. (2026) · Neuroethics · doi:10.1007/s12152-026-09663-3 · Cited by 2
A Naturalistic Evaluation of Change in Antidepressant Prescription in Patients With Affective and Anxiety Disorders in a Tertiary Care Hospital of India
Patil, A., Sahoo, S., Garg, G., & Grover, S. (2017) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000822 · Cited by 2
Study protocol on the efficacy of exergames-acceptance and commitment therapy program for the treatment of major depressive disorder: Comparison with acceptance and commitment therapy alone and treatment-as-usual in a multicentre randomised controlled trial
Zhang, B., Deng, H., Ren, J., Legrand, F. D., Ahmad Yusof, H., Zhang, R., & Leong Bin Abdullah, M. F. I. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-080315 · Cited by 2
“33 Hence, novel treat-ment strategies are needed to enhance the efficacy of treatment for depression.”
Background
The Association of Different Types of Intermittent Fasting with Mental Health: A Protocol for Systematic Review
Rabiei, S. (2025) · International Journal of Preventive Medicine · doi:10.4103/ijpvm.ijpvm_312_24 · Cited by 1
Personalized continuation therapy with SAINT for maintaining remission in treatment-resistant depression
Stimpson, K. H., Feyder, M. T., Maron‐Katz, A., Kiris, E., Ford, T. J., Carreon, D. M., DeSouza, D. D., Cole, E. J., Meng, N. F., Williams, N., et al. (2025) · Transcranial magnetic stimulation . · doi:10.1016/j.transm.2025.100203 · Cited by 2
Has Deep Brain Stimulation Shown Its Full Potential in Treatment-Resistant Depression? A Scoping Review
Liene, P., Amoussou, J. R., von Gunten, A., & Elowe, J. (2025) · Biological Psychiatry Global Open Science · doi:10.1016/j.bpsgos.2025.100682 · Cited by 2
Investigating the effect of intermittent fasting (time-restricted eating) with and without calorie restriction compared to calorie restriction on anthropometric parameters, depression score, and metabolic factors in patients with major depression disorder and obesity: a study protocol for a randomized controlled trial
Karimi, A. B., Alamdari, N. M., Hosseini, L., & Maghsoumi‐Norouzabad, L. (2026) · Trials · doi:10.1186/s13063-026-09860-8 · Cited by 1
A Randomized, Double-blind Study of the Efficacy and Tolerability of Extended Release Quetiapine Fumarate (Quetiapine XR) Monotherapy in Patients with Major Depressive Disorder
Wang, G., McIntyre, A., Earley, W. R., Raines, S. R., & Eriksson, H. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4057 · Cited by 1
Citalopram is less effective for patients with neurological disorder and/or post-traumatic stress disorder
Alemi, F., Mazloum-Yazdi, A., & Peppard, L. (2017) · Personalized Medicine in Psychiatry · doi:10.1016/j.pmip.2017.07.003 · Cited by 1
Is MDD the right target for early-stage psychedelic-assisted therapy trials?
Lewis, B. R., & Byrne, K. (2021) · Journal of Psychedelic Studies · doi:10.1556/2054.2021.00180 · Cited by 1
Maintenance of antidepressant effect by dextromethorphan in patients with treatment-resistant depression who respond to ketamine intervention
Chen, M.-H., & Tsai, S. (2024) · Medical Hypotheses · doi:10.1016/j.mehy.2023.111242 · Cited by 1
Effects of Adjunctive Ketamine Intravenous Infusion in Taiwanese Patients with Treatment-Resistant Depression: Antidepression, Antisuicidality, BDNF Val66Met, and Brain Imaging
Chen, M., & Su, T. (2020) · Springer eBooks · doi:10.1007/978-981-15-2902-3_11 · Cited by 1
Current use of deep brain stimulation for treatment-resistant depression in different geographic regions of the world
Xu, J. (2022) · International Journal of Frontiers in Medicine · doi:10.25236/ijfm.2022.041107
Summaries of plenary, symposia, and oral sessions at the XXII World Congress of Psychiatric Genetics, Copenhagen, Denmark, 12–16 October 2014
Aas, M., Blokland, G. A. M., Chawner, S. J. R. A., Choi, S. W., Estrada, J., Forsingdal, A., Friedrich, M. U., Ganesham, S., Hall, L. S., Haslinger, D., et al. (2015) · Psychiatric Genetics · doi:10.1097/ypg.0000000000000112
Treatment-resistant depression and the elephant in the room
Jenkins, E. (2010) · Summit (Simon Fraser University)
Oncodynamic Effect of Cancer on Depression
Nashed, M. G., Frey, B. N., Rosebush, P. I., & Singh, G. (2016) · Springer eBooks · doi:10.1007/978-3-319-28558-0_6
Neuroimmunopharmacology at the Interface of Inflammation and Pharmacology Relevant to Depression
Holmes, J., Corrigan, F., & Hutchinson, M. R. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811073-7.00012-x
The role of pharmacogenetics in the treatment of depression
Chan, A. R., Gorbovskaya, I., & Müller, D. J. (2019) · Oxford University Press eBooks · doi:10.1093/oso/9780198793014.003.0027
Neural and genetic correlates of cognitive deficits in major depressive disorder
Herzallah, M. M., Miezah, D., & Moustafa, A. A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-817676-4.00002-x

Authors: Howland, R. H.
Affiliations: University of Pittsburgh (US)
Corresponding author: Howland, Robert H.
ORCID: Howland, Robert H.
Venue: Journal of Psychosocial Nursing and Mental Health Services
Publisher: SLACK, Inc.
Published: 2008-10
Volume: 46
Issue: 10
Pages: 21-24
ISSN: 0279-3695 (ISSN-L)
1938-2413
DOI: 10.3928/02793695-20081001-05
OpenAlex: W146502225
Cited by: 115
References: 15
Citations by year: 2026: 5 · 2025: 14 · 2024: 9 · 2023: 12 · 2022: 9 · 2021: 7 · 2020: 7 · 2019: 9 · 2018: 7 · 2017: 7 · 2016: 3 · 2015: 10 · 2014: 3 · 2013: 2 · 2012: 3
FWCI: 1.87
Type: journal article
Language: en
Open access: closed
Locations: Journal of Psychosocial Nursing and Mental Health Services (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
Keywords: depression, antidepressants, STAR*D, sequential therapy, citalopram, remission, treatment response, treatment intolerance, relapse, patient preferences, antidepressant efficacy
MeSH terms: Antidepressive Agents, Combined Modality Therapy, Depressive Disorder, Humans, Remission Induction, Research Design, Randomized Controlled Trials as Topic, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Sequenced Treatment Alternatives to Relieve Depression (STAR*D): Part 2: Study Outcomes

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks